
Impact Score
Impact Score


| Metric | Value | Unit | Year | PDF Name | PDF Page | |
|---|---|---|---|---|---|---|
CEO-to-Employee Pay Ratio | ||||||
| 1 009 004 | ($) | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 30 | ||
| 227 | employees | 2024 | 0001140361-25-016323.pdf | 33 | ||
| 57 383 | dollars in thousands): | 2024 | 0001140361-25-016323.pdf | 108 | ||
| David Kirn | 2024 | 0001140361-25-016323.pdf | 123 | |||
Harassment and Discrimination at the Workplace | ||||||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 2 | |||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 10 | |||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 2 | |||
| Yes | 2024 | 4DMT - Code of Business Conduct and Ethics (2024).pdf | 3 | |||
Union Formation and Collective Bargaining Power | ||||||
| 0 | employees | 2024 | 0001140361-25-016323.pdf | 33 | ||
| 227 | employees | 2024 | 0001140361-25-016323.pdf | 33 | ||
Women on the Board | ||||||
| 7 | members | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 19 | ||
| 5 | Name | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 28 | ||
| 0 | Name | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 28 | ||
| 2 | Name | 2024 | SEC Filing | 4D Molecular Therapeutics.pdf | 11 | ||
